AU2002220404A1 - Method for treating thrombocytopenia with monoclonal ivig - Google Patents

Method for treating thrombocytopenia with monoclonal ivig

Info

Publication number
AU2002220404A1
AU2002220404A1 AU2002220404A AU2040402A AU2002220404A1 AU 2002220404 A1 AU2002220404 A1 AU 2002220404A1 AU 2002220404 A AU2002220404 A AU 2002220404A AU 2040402 A AU2040402 A AU 2040402A AU 2002220404 A1 AU2002220404 A1 AU 2002220404A1
Authority
AU
Australia
Prior art keywords
ivig
monoclonal
treating thrombocytopenia
thrombocytopenia
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002220404A
Inventor
Andrew R. Crow
John Freedman
Alan H. Lazarus
Seng Song
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Canadian Blood Services
Original Assignee
Canadian Blood Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canadian Blood Services filed Critical Canadian Blood Services
Publication of AU2002220404A1 publication Critical patent/AU2002220404A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to a method and composition utilizing monoclonal intravenous immunoglobulin (mlVIG) for increasing platelet cell counts in thrombocytopenia The method and composition are suitable for treatments of patients suffering from medical conditions, such as idiopathic thrombocytopenic purpura (ITP) which result in low platelet cell numbers
AU2002220404A 2000-11-20 2001-11-20 Method for treating thrombocytopenia with monoclonal ivig Abandoned AU2002220404A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24944100P 2000-11-20 2000-11-20
US60/249,441 2000-11-20
PCT/CA2001/001648 WO2002040047A2 (en) 2000-11-20 2001-11-20 Method for treating thrombocytopenia with monoclonal ivig

Publications (1)

Publication Number Publication Date
AU2002220404A1 true AU2002220404A1 (en) 2002-05-27

Family

ID=22943488

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002220404A Abandoned AU2002220404A1 (en) 2000-11-20 2001-11-20 Method for treating thrombocytopenia with monoclonal ivig

Country Status (7)

Country Link
US (1) US20040047862A1 (en)
EP (2) EP2283861B1 (en)
AT (1) ATE540694T1 (en)
AU (1) AU2002220404A1 (en)
CA (2) CA2856033C (en)
DK (2) DK1370288T3 (en)
WO (1) WO2002040047A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0314461D0 (en) * 2003-06-20 2003-07-23 Isis Innovation Suppression of transplant rejection
US20080050391A1 (en) * 2004-03-30 2008-02-28 Lazarus Alan H Method for Treating Autoimmune Diseases With Antibodies
US8470318B2 (en) 2005-11-07 2013-06-25 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US8597636B2 (en) 2006-01-13 2013-12-03 Canadian Blood Services Method for treating autoimmune diseases and compositions therefor
EA022780B1 (en) 2006-04-05 2016-03-31 Дзе Рокфеллер Юниверсити Method for enhancing anti-inflammatory activity and decreasing cytotoxic activity of igg preparation
MX2010011598A (en) 2008-04-22 2010-12-15 Univ Rockefeller Methods of identifying anti-inflammatory compounds.
US20150329639A1 (en) * 2012-12-12 2015-11-19 University Of Virginia Patent Foundation Compositions and methods for regulating erythropoiesis
NZ722055A (en) 2013-12-24 2020-02-28 Univ Texas Fcrn antagonists and methods of use
JP2018509413A (en) 2015-03-09 2018-04-05 アルゲン−エックス ビーブイビーエー Methods for reducing serum levels of Fc-containing agents using FcRn antagonists
GB2589049C (en) 2019-04-11 2024-02-21 argenx BV Anti-IgE antibodies
SG11202112010RA (en) 2019-06-07 2021-12-30 Argenx Bvba PHARMACEUTICAL FORMULATIONS OF FcRn INHIBITORS SUITABLE FOR SUBCUTANEOUS ADMINISTRATION
MX2022008320A (en) 2020-01-08 2022-10-21 argenx BV Methods for treating pemphigus disorders.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993812A (en) * 1995-09-14 1999-11-30 Cangene Corporation Method of delaying the progression of an infection with the human immunodeficiency virus
JPH0987202A (en) * 1995-09-20 1997-03-31 Sumitomo Pharmaceut Co Ltd Blood coagulation abnormality therapeutic agent
WO1999000143A1 (en) * 1997-06-27 1999-01-07 Biogen, Inc. Cd154 blockade therapy for autoimmune diseases
US5980893A (en) * 1997-07-17 1999-11-09 Beth Israel Deaconess Medical Center, Inc. Agonist murine monoclonal antibody as a stimulant for megakaryocytopoiesis
DK1176981T3 (en) * 1999-05-07 2006-04-10 Genentech Inc Treatment of autoimmune diseases with antagonists that bind to B cell surface markers
US20030095966A1 (en) * 2000-03-29 2003-05-22 Yang Liu Method of blocking tissue destruction by autoreactive T cells
JP2004508420A (en) * 2000-09-18 2004-03-18 アイデック　ファーマスーティカルズ　コーポレイション Combination therapy for treating autoimmune diseases using B cell depleting antibody / immunomodulatory antibody combination
AUPR540301A0 (en) * 2001-06-01 2001-06-28 Walter And Eliza Hall Institute Of Medical Research, The A method of purification of cells

Also Published As

Publication number Publication date
EP2283861A3 (en) 2013-05-29
WO2002040047A2 (en) 2002-05-23
EP2283861B1 (en) 2016-01-27
DK1370288T3 (en) 2012-03-05
EP1370288A2 (en) 2003-12-17
ATE540694T1 (en) 2012-01-15
EP2283861A2 (en) 2011-02-16
CA2467781A1 (en) 2002-05-23
DK2283861T3 (en) 2016-02-15
US20040047862A1 (en) 2004-03-11
EP1370288B1 (en) 2012-01-11
CA2856033A1 (en) 2002-05-23
WO2002040047A3 (en) 2003-10-02
CA2467781C (en) 2014-09-23
CA2856033C (en) 2015-11-03

Similar Documents

Publication Publication Date Title
EP2283861A3 (en) Method for Treating Thrombocytopenia with Monoclonal IVIG
NZ568403A (en) CD20-specific antibodies and methods of employing same
SG170110A1 (en) Identification and engineering of antibodies with variant heavy chains and methods of using same
TW200716677A (en) Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
NZ603883A (en) Method for preparing antibodies having improved properties
WO2002072605A3 (en) Expression technology for proteins containing a hybrid isotype antibody moiety
WO2004070011A3 (en) HIGH AFFINITY ANTI-HUMAN IgE ANTIBODIES
UA83791C2 (en) Antibody to vla-1, pharmaceutical composition, containing thereof, and use of them for treatment individual having immunological disorder, mediated by vla-1
WO2006113643A3 (en) High affinity fully human monoclonal antibodies to interleukin-8 and epitopes for such antibodies
WO2004016769A3 (en) Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof
SG156547A1 (en) Human monoclonal antibodies to ctla-4
NZ590863A (en) Anti-hepcidin-25 selective antibodies and uses thereof
WO2006055638A3 (en) Fully human monoclonal antibodies to il-13
ATE447587T1 (en) ANTI-IL-20 ANTIBODIES AND BINDING PARTNERS AND METHOD FOR USE IN INFLAMMATION
EP1594441A4 (en) Method for treating pain by administering a nerve growth factor antagonist and an nsaid and composition containing the same
TW200637873A (en) Antibodies against interleukin-1 beta
EP1578799B8 (en) Antibodies directed to tumor necrosis factor and uses thereof
NZ595011A (en) Humanised antibodies that bind and inhibit human DKK-1 protein and composition containing antibodies for treating DKK-1 associated diseases
IL148079A0 (en) Human ctla-4 antibodies and compositions containing the same
SG153878A1 (en) Chimeric and humanised monoclonal antibodies against inteleukin-13
TR200102733T2 (en) Recombinant IL-18 antagonists useful in the treatment of IL-18 related disorders
WO2005012358A3 (en) Use of adcc-optimized antibodies for treating weak patients
WO2005000194A3 (en) Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
DE60328747D1 (en) Purification of polyreactive autoantibodies and their uses
WO2002015846A3 (en) Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders